Medicare Enrolled

Dr. Yvonne Manalo, MD

Medical Oncology · Corpus Christi, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
1625 RODD FIELD RD STE 100, Corpus Christi, TX 78412
3618870067
In practice since 2006 (20 years)
NPI: 1619956596 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Manalo from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Manalo? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Manalo

Dr. Yvonne Manalo is a medical oncology in Corpus Christi, TX, with 20 years in practice. Based on federal Medicare data, Dr. Manalo performed 116,793 Medicare services across 829 unique beneficiaries.

Between the years covered by Open Payments, Dr. Manalo received a total of $17,513 from 72 pharmaceutical and/or device companies across 917 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Manalo is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice▲ Top 7% volume in TX$ $17,513 industry payments

Medicare Practice Summary

Medicare Utilization ↗
116,793
Medicare services
Top 7% in TX for medical oncology
829
Unique beneficiaries
$7
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~5,840 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Filgrastim injection (Nivestym) for white blood cells91,620$0$1
Pembrolizumab injection (Keytruda)13,600$43$80
Anti-nausea injection (ondansetron/Zofran)4,276$0$1
Dexamethasone injection (steroid)3,541$0$0
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less830$22$60
Injection, carboplatin, 50 mg493$2$5
Administration of chemotherapy into vein, 1 hour or less440$97$275
Office visit, established patient (30-39 min)423$95$160
Drug injection, under skin or into muscle375$10$40
Injection, diphenhydramine hcl, up to 50 mg270$1$2
Office visit, established patient (20-29 min)245$60$150
Telephone medical discussion with physician, 11-20 minutes188$62$160
Administration of chemotherapy into vein, each additional hour159$21$60
Administration of additional new drug or substance into vein, 1 hour or less108$49$135
Hospital follow-up visit, moderate complexity70$61$135
New patient office visit, complex (60-74 min)65$160$400
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less46$46$140
Irrigation of implanted venous access drug delivery device44$17$50
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.8% high complexity
98.3% medium
1.0% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$17,513
Total received (2018-2024)
Avg $2,502/year across 7 years
Top 32% in TX for medical oncology
72
Companies
917
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$16,548 (94.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$965 (5.5%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$3,703
2023
$2,993
2022
$2,420
2021
$2,176
2020
$1,244
2019
$2,561
2018
$2,414

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$1,782
Novartis Pharmaceuticals Corporation
$1,604
PFIZER INC.
$1,210
AstraZeneca Pharmaceuticals LP
$1,157
Janssen Biotech, Inc.
$1,036
Incyte Corporation
$755
Genentech USA, Inc.
$729
Merck Sharp & Dohme LLC
$722
Celgene Corporation
$466
Astellas Pharma US Inc
$434
Lilly USA, LLC
$414
Merck Sharp & Dohme Corporation
$406
Takeda Pharmaceuticals U.S.A., Inc.
$373
GENZYME CORPORATION
$369
Gilead Sciences, Inc.
$325
Eisai Inc.
$320
Daiichi Sankyo Inc.
$313
Exelixis Inc.
$261
Karyopharm Therapeutics Inc.
$255
Kite Pharma, Inc.
$252
Seagen Inc.
$244
GlaxoSmithKline, LLC.
$241
Regeneron Healthcare Solutions, Inc.
$225
ADC Therapeutics America, Inc.
$210
Taiho Oncology, Inc.
$184
Boehringer Ingelheim Pharmaceuticals, Inc.
$170
Stryker Corporation
$170
Ipsen Biopharmaceuticals, Inc
$169
AbbVie, Inc.
$162
AVEO Pharmaceuticals, Inc.
$159
TAIHO ONCOLOGY, INC.
$148
BeiGene USA, Inc.
$138
Puma Biotechnology, Inc.
$133
EMD Serono, Inc.
$130
Pharmacyclics LLC, An AbbVie Company
$128
ABBVIE INC.
$115
ARRAY BIOPHARMA INC
$111
Janssen Scientific Affairs, LLC
$105
Dova Pharmaceuticals
$102
SOBI, INC
$100
SANOFI-AVENTIS U.S. LLC
$100
EISAI INC.
$84
MorphoSys, US Inc.
$78
Bayer Healthcare Pharmaceuticals Inc.
$76
PUMA BIOTECHNOLOGY, INC.
$71
Mirati Therapeutics, Inc.
$68
Pharmacyclics LLC, an AbbVie Company
$58
TESARO, Inc.
$48
Seattle Genetics, Inc.
$45
Bayer HealthCare Pharmaceuticals Inc.
$44
Clovis Oncology, Inc.
$40
Myovant Sciences Inc.
$38
AbbVie Inc.
$37
Blueprint Medicines Corporation
$32
Stemline Therapeutics Inc.
$31
JAZZ PHARMACEUTICALS INC.
$30
Sandoz Inc.
$29
SECURA BIO, INC.
$29
Epizyme, Inc.,
$28
Sobi, Inc
$22
Organon LLC
$20
ImmunoGen, Inc.
$20
Coherus Biosciences Inc.
$20
TG THERAPEUTICS, INC.
$19
Immunomedics, Inc.
$18
Spectrum Pharmaceuticals Inc.
$17
SHIELD THERAPEUTICS INC
$15
Tolmar, Inc.
$15
SpringWorks Therapeutics, Inc.
$15
Acrotech Biopharma LLC
$15
Secura Bio, Inc.
$12
Mylan Institutional Inc.
$12
Top 3 companies account for 26.2% of total payments
Associated products mentioned in payments ›
ABECMA · ACCRUFER · ADCETRIS · AFINITOR · ALIMTA · ALUNBRIG · Abraxane · Alecensa · Aliqopa · Avastin · BALVERSA · BAVENCIO · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Bavencio · CABOMETYX · CALQUENCE · COPIKTRA · CYRAMZA · Cabometyx · Columvi · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELIGARD · ELIQUIS · ELITEK · EMPLICITI · ENHERTU · ENJAYMO · EPKINLY · Elahere · Enhertu · Erleada · FARYDAK · FOLOTYN · FOTIVDA · FRUZAQLA · Fabhalta · Folotyn · GAVRETO · GAZYVA · GILOTRIF · Gazyva · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INLYTA · INQOVI · Imbruvica · Inrebic · Itovebi · JADENU · JAKAFI · JEMPERLI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · LIBTAYO · LONSURF · LORBRENA · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · MYLOTARG · NERLYNX · NINLARO · Nerlynx · Nubeqa · OGSIVEO · OJJAARA · ONTRUZANT · OPDIVO · OPDUALAG · ORGOVYX · Ogivri · Onivyde · Orserdu · PADCEV · PIQRAY · PLUVICTO · PROMACTA · Padcev · Perjeta · Phesgo · Pomalyst · REBLOZYL · RETEVMO · RYDAPT · Revlimid · Rubraca · SANDOSTATIN · SARCLISA · SCEMBLIX · SHINGRIX · SOMATULINE DEPOT · SPRYCEL · SPY-PHI SYSTEM · SUTENT · Somatuline Depot · Stivarga · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TIVDAK · TUKYSA · Tecentriq · Tecentriq Hybreza · Trodelvy · UKONIQ · Udenyca · VENCLEXTA · VERZENIO · VOTRIENT · Venclexta · WELIREG · XALKORI · XOSPATA · XPOVIO · XTANDI · Xofigo · Xospata · Xtandi · Yescarta · ZARXIO · ZEJULA · ZEPZELCA · ZIEXTENZO · ZYTIGA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (94%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $15 per 100 Medicare services performed
Looking for a medical oncology in Corpus Christi?
Compare medical oncologys in the Corpus Christi area by procedure volume, costs, and industry payment transparency.
Browse medical oncologys nearby

Geographic Context

Medical Oncologys within 10 mi
2
Per 100K population
0.6
County median income
$66,021
Nearest hospital
CORPUS CHRISTI MEDICAL CENTER,THE
3.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Manalo is a mixed practice specialist, with above-average Medicare volume (top 7% in TX), and low-engagement industry engagement, with 20 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Manalo experienced with filgrastim injection (nivestym) for white blood cells?
Based on Medicare claims data, Dr. Manalo performed 91,620 filgrastim injection (nivestym) for white blood cells services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Manalo receive payments from pharmaceutical companies?
Yes. Dr. Manalo received a total of $17,513 from 72 companies across 917 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Manalo's costs compare to other medical oncologys in Corpus Christi?
Dr. Manalo's average Medicare payment per service is $7. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Manalo) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →